Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: Membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5779-5786

  Papo, Niv ^a   Braunstein, Amir ^a   Eshhar, Zelig ^a   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANDROGEN; ANTINEOPLASTIC AGENT; CALCEIN; CYCLOPHOSPHAMIDE; DEXTRO AMINO ACID; DOXORUBICIN; LEUCINE; LEUCYLLYSYLLEUCYLLEUCYLLYSYLLYSYLLEUCYLLEUCYLLYSYLLYSYLLEUCYLLEUCYLLYSYLLEU CYLLEUCINAMINE; LYSINE; PROSTATE SPECIFIC ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOLYSIS; DIASTEREOISOMER; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

AMINO ACIDS; ANDROGENS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG SYNERGISM; FLUORESCEINS; HUMANS; MALE; MEMBRANE POTENTIALS; MICE; NECROSIS; NEOPLASMS, HORMONE-DEPENDENT; NIH 3T3 CELLS; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEREOISOMERISM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4143110396     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1438     Document Type: Article

References (51)

1. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer (Phila) 1993;71:880-6.
2. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA - Cancer J Clin 1995;45:8-30.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA - Cancer J Clin 1998;48:6-29.
4. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001;15:525-45.
5. Thomas T, Balabhadrapathruni S, Gallo MA, Thomas TJ. Development of polyamine analogs as cancer therapeutic agents. Oncol Res 2002;13:123-35.
6. Morrissey C, Watson RW. Phytoestrogens and prostate cancer. Curr Drug Targets 2003;4:231-41.
7. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999;54:30-5.
8. Beer T, Raghavan D. Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder. Prostate 2000;45:184-93.
9. van Brussel JP, Busstra MB, Lang MS, et al. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2000;45:509-12.
10. Howell SB. Resistance to apoptosis in prostate cancer cells. Mol Urol 2000;4:225-9.
11. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 1998;17:345-51.
12. Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002;50:46-52.
13. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002;277:47928-37.
14. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 1993;53:3052-7.
15. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
16. Chen Y, Xu X, Hong S, et al. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001;61:2434-8.
17. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD. A proapoptotic pepdde for the treatment of solid tumors. Cancer Res 2001;61:7709-12.
18. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995;13:61-92.
19. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-53.
20. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-6.
21. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003;62:ii17-21.
22. Hui L, Leung K, Chen HM. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 2002;22:2811-6.
23. Shin SY, Lee SH, Yang ST, et al. Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. J Pept Res 2001;58:504-14.
24. Park Y, Lee DG, Jang SH, et al. A Leu-Lys-rich antimicrobial peptide: activity and mechanism. Biochim Biophys Acta 2003;21:172-82.
25. Warren P, Li L, Song W, et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res 2001;61:6783-7.
26. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003;78:17-27.
27. Wang Z, Wang G. APD: the antimicrobial peptide database. Nucleic Acids Res 2004;32:D590-2.
28. Chan SC, Yau WL, Wang W, et al. Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. J Pept Sci 1998;4:413-25.
29. Papo N, Shai Y. New lytic peptides based on the D, L amphipathic helix motif preferentially kill tumor cells compared with nornal cells. Biochemistry 2003;42:9346-54.
30. Oren Z, Shai Y. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: Structure-function study. Biochemistry 1996;36:1826-35.
31. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of D, L amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003;278:21018-23.
32. Patel BJ, Pantuck AJ, Zisman A, et al. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-5.
33. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9.
34. Horoszewicz JS, Leong SS, Chu TM, et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-32.
35. Merrifield RB, Vizioli LD, Boman HG. Synthesis of the antibacterial peptide cecropin A (1-33). Biochemistry 1982;21:5020-31.
36. Pouny Y, Shai Y. Interaction of D-amino acid incorporated analogues of pardaxin with membranes. Biochemistry 1992;31:9482-90.
37. Allen TM, Cleland LG, Serum-induced leakage of liposome contents. Biochim Biophys Acta 1980;597:418-26.
38. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992;36:2201-3.
39. Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51:73-83.
40. Habermann E, Jentsch J. Hoppe Seyler's Z. Physiol Chem 1967;348:37-50.
41. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 1998;273:3718-24.
42. Kelloff GJ, Lieberman R, Steele VE, et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001;57:46-51.
43. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998;8:437-41.
44. Papo N, Oren Z, Pag U, Sahl HG, Shai Y. The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem 2002;277:33913-21.
45. Papo N, Shai Y. Effect of drastic sequence alteration and d-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry 2004;43:6393-403.
46. Cappelli G, Paladini S, D'Agata A. Tumor markers in the diagnosis of pancreatic cancer. Tumori 1999;85:S19-21.
47. Chen HM, Wang W, Smith D, Chan SC. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochim Biophys Acta 1997;1336:171-9.
48. Hendrich AB, Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets 2003;4:23-30.
49. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today 1995;16:194-201.
50. Benkirane N, Friede M, Guichard G, et al. Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a Denantiomer do recognize the parent L-hexapeptide and reciprocally. J Biol Chem 1993;268:26279-85.
51. An J, Sun YP, Adams J, et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003;9:4537-45.